Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $74.50 Average Target Price from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $74.50.

Several equities research analysts have commented on the company. JMP Securities cut their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. TD Cowen lowered their price target on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. B. Riley lowered their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Finally, William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th.

Lantheus Trading Down 1.3%

NASDAQ LNTH opened at $55.60 on Thursday. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 14.79 and a beta of 0.09. The stock’s 50 day moving average price is $53.91 and its two-hundred day moving average price is $73.12. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. Lantheus has a 52 week low of $47.25 and a 52 week high of $118.21.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. As a group, analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,812,000 shares of company stock worth $382,427,380 in the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. bought a new stake in Lantheus in the 3rd quarter valued at $65,654,000. TD Asset Management Inc boosted its stake in Lantheus by 1,028.0% in the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock valued at $66,623,000 after purchasing an additional 622,100 shares during the period. Nuveen LLC bought a new stake in Lantheus in the 1st quarter valued at $55,941,000. Norges Bank bought a new stake in Lantheus in the 2nd quarter valued at $32,631,000. Finally, Epoch Investment Partners Inc. bought a new stake in Lantheus in the 1st quarter valued at $35,548,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.